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PHeart Rhythm Disorders: Viewpoint
he Growing Mismatch Between
atient Longevity and the Service Life
f Implantable Cardioverter-Defibrillators
obert G. Hauser, MD, FACC.
inneapolis, Minnesota
Implantable cardioverter-defibrillators (ICDs) are lifesaving devices. Over 100,000 patients
received ICDs in 2004 at a cost of $2 billion for the pulse generators alone. Because of
expanded indications and coverage by Medicare, the number of ICD implantations and
replacements is expected to increase dramatically during the next decade. The average ICD
patient at our institution now lives nearly 10 years after the procedure. However, the service
life of pulse generators has decreased from 4.7  1 year for single-chamber units to 4.0  1
year for dual-chamber devices. This mismatch between patient longevity and the service life
of ICDs poses a significant clinical and economic burden that must be addressed. One
near-term solution is for manufacturers to provide devices with larger batteries so that most
patients can have an ICD pulse generator that lasts a lifetime. For the long-term, more robust
or renewable energy sources are needed. (J Am Coll Cardiol 2005;45:2022–5) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.077the American College of Cardiology Foundation
s
c
I
T
I
s
a
a
y
t
i
a
t
r
l
I
T
f
g
d
d
b
I
I
t
8
y
t
sver 100,000 patients received implantable cardioverter-
efibrillators (ICDs) in 2004. At an estimated average
elling price of $20,000, the ICD pulse generators alone cost
2 billion. The majority of these implants were dual-
hamber models, and a substantial number were devices that
re capable of cardiac resynchronization therapy (CRT).
ased on data from the Multicenter Registry (1,2) and an
nalysis of our institution’s ICD patient population, it is
ikely that 70% of pulse generators implanted in 2004 will
equire replacement because of battery depletion over the
ext five years. This means that approximately $1.4 billion
ill be spent to purchase replacement pulse generators for
atients who underwent implantation last year. These initial
nd replacement pulse generator costs are exclusive of hospital
harges, provider fees, and expenses associated with leads,
ollow-up care, and surgical complications.
The cost of ICD therapy is balanced by the clinical
enefits. Multiple clinical trials have shown that ICD
herapy prevents sudden cardiac death in susceptible popu-
ations (3–7), and current evidence suggests that the addi-
ion of CRT is clinically important for selected patients
8–10). Although improved risk stratification may decrease
he number of ICD implants, the medical community,
ayers, and industry must collaborate to reduce ICD costs.
he most feasible near-term solution is for industry to
rovide pulse generators with larger, longer-life batteries.
uture ICD pulse generators should have robust energy
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005, accepted February 28, 2005.ources that can be renewed, e.g., be rechargeable without
ostly surgery.
CD PATIENT LONGEVITY
he cumulative survival of 1,280 patients who have received
CDs since 1987 at the Minneapolis Heart Institute is
hown in Figure 1. The probability of a patient living 4, 5,
nd 6 years after ICD implantation is 79  1%, 75  1%,
nd 68  2%. Over 40% of patients were still living at 10
ears. The average ejection fraction was 34  15%, and
hese patients had ischemic heart disease (73%), non-
schemic cardiomyopathy (13%), hypertrophic cardiomyop-
thy (5%), and other cardiac conditions. These data suggest
hat the majority of ICD patients would not require a
eplacement procedure for battery depletion if the service
ife of ICD models was at least 10 years.
CD PULSE GENERATOR SERVICE LIFE
he Multicenter Registry has gathered ICD pulse generator
ailure data since 1999. To date, of 1,107 ICD pulse
enerator failures, 90% were caused by normal battery
epletion and 10% were caused by electronic or housing
efects. The majority of pulse generators were manufactured
y Guidant Inc. (St. Paul, Minnesota) (49%), Medtronic
nc. (Minneapolis, Minnesota) (31%), and St. Jude Medical
nc. (St. Paul, Minnesota) (19%). The average service life of
hese pulse generators was 4.3  1.5 years (range 1 day to
.9 years). Only 5% of pulse generators functioned for seven
ears. After excluding non-battery failures caused by elec-
ronic or housing defects, the average service life of 814
ingle-chamber pulse generators was 4.7 1 year compared
ith 4.0  1 year for 293 dual-chamber pulse generators
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June 21, 2005:2022–5 Growing Mismatchp  0.0001). Thus, the service life of contemporary ICD
odels is far less than the expected patient longevity, and
he shift to dual-chamber models has significantly shortened
attery life. The growing proportion of dual-chamber im-
lants may be inappropriate because patients who do not
equire bradycardia pacing support may be adversely affected
y right ventricular stimulation (11).
OST EFFECTIVENESS
n the U.S., the generally accepted benchmark for econom-
cally attractive cost-effective care is $50,000 per life year.
he cost effectiveness of ICDs depends, in part, on the
opulation being studied and the frequency and cost of
ulse generator replacement. A recent study by the Blue
ross Blue Shield Association (12) evaluated the cost
ffectiveness of ICDs in the Multicenter Automatic Defi-
rillator Implantation Trial (MADIT)-II population. The
ase case assumed a 7-year pulse generator lifespan and a 67%
eduction in sudden cardiac death. Given these assump-
ions, the investigators estimated that the cost effectiveness
f ICDs was $51,000 per quality-adjusted life year (QALY).
ensitivity analyses showed that cost effectiveness was
44,300 per QALY if the pulse generator was replaced every
1 years but decreased to $58,100 per QALY if the pulse
enerator was replaced every 5 years. Based on the average
ongevity of devices in the Multicenter Registry’s database,
he base-case assumption overestimated the cost effective-
ess of ICDs. Nevertheless, this study showed how impor-
ant pulse generator longevity is to the cost-effective appli-
ation of ICD therapy.
Abbreviations and Acronyms
CRT  cardiac resynchronization therapy
ICD  implantable cardioverter-defibrillator
QALY  quality-adjusted life year2
igure 1. Survival of patients after implantable cardioverter-defibrillator
mplantation. SE  standard error of the mean.FFECT OF BATTERY CAPACITY ON SERVICE LIFE
he ICD pulse generators use proprietary lithium silver
anadium oxide batteries that are capable of delivering
mpere-level current. One manufacturer (Guidant Inc.) has
ffered four ICD models with a choice of battery capacities,
.e., a standard battery (0.92 to 1.06 AmpHr) or a large
attery (1.44 to 1.75 AmpHr). This allowed a multicenter
omparison of the effect of different battery capacities on
ulse generator service life (13). The results are shown in
igure 2. Large-capacity batteries increased average service
ife by 2.3 years. The number of therapeutic shocks did not
eem to affect battery longevity in either group. Large-
apacity batteries increased pulse generator size and weight
y 5 cc and 11 g. The added battery longevity reduced
nnual pulse generator costs by $1,000 to $1,600 per patient.
hese data suggest that larger batteries can reduce costs by
ignificantly prolonging the service life of ICDs with only a
mall increase in pulse generator size.
Physicians tend to believe that patients would resist any
ncrease in pulse generator size. However, a recent study by
ild et al. (14) found that 90% of patients thought that
CD and pacemaker longevity was more important than
ize. The vast majority of patients preferred a larger device
hat could reduce the number of potential replacement
rocedures. This preference was consistent across the spec-
rum of patients with a previous implant, those undergoing
nitial implantations, those returning for routine follow-up,
nd patients of various ages, gender, and body habitus.
owever, large pulse generators may increase the risk of
ocket complications, including erosion and discomfort,
nd some patients may not be suitable candidates for such
odels.
Physicians are also concerned that a long-lived pulse
enerator may become technologically obsolete as newer
odels are introduced. Consequently, it is argued that
atients may be denied the benefits of new features or
unctions. Such reservations, however, are not supported by
linical studies that quantify the risks and benefits of regular
ulse generator replacement. Moreover, pulse generator
eplacement is associated with known complications, in-
luding infection and the potential for lead damage. More
han one-half of all pacemaker and ICD infections occur
fter replacement procedures (15). An ICD infection often
equires complex lead extraction that is associated with
ignificant morbidity and mortality (16). Thus, pulse gen-
rator replacement is not desirable except in patients whose
linical circumstances warrant the risks and costs of upgrad-
ng to a new model.
The growing economic burden of ICD therapy is likely to
ccelerate as more ICD implants include CRT. These
evices are more expensive and use more energy than
tandard ICDs. Over the past 5 years, the Minneapolis
eart Institute’s annual new and replacement ICD implan-
ations have more than doubled from 148 in 2000 to 326 in
004 (Fig. 3). In addition, the proportion of ICDs with
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Growing Mismatch June 21, 2005:2022–5RT capability (ICD-CRT) has increased from nil in 2000
o 44% in 2004. During this same period, our hospital’s total
CD device supply costs increased from $2.6 to $7.0
illion, and ICD-CRT models accounted for 55% of ICD
evice costs in 2004 (Fig. 4). The growth and shift to
CD-CRT models were driven by the results of clinical
rials rather than changes in our practice or patient popu-
ation. With the recent publication of the Sudden Cardiac
eath in Heart Failure Trial (SCD-HeFT) (7), we expect a
ubstantial increase in the number of ICD-eligible patients,
nd device costs will grow accordingly.
Unfortunately, as of this writing, only one manufacturer
rovides a large-battery-capacity ICD, and this option is
vailable for one dual-chamber model. Thus, we do not have
he choice of implanting large-battery-capacity single-
hamber or CRT ICDs because they are not available. The
CD manufacturers have no incentive to provide long-lived
ulse generators. Indeed, the opposite is true, namely
requent replacements increase sales and profits. Although
echargeable batteries exist, they are not being used.
igure 2. Longevity of standard and large-battery-capacity implantable
ardioverter-defibrillator pulse generators. Non-battery failures were cen-
ored. SE  standard error of the mean.
igure 3. The implantable cardioverter defibrillator (ICD) implants at the
inneapolis Heart Institute during the past five years. CRT  cardiac
esynchronization therapy.hereas hospitals could benefit financially by using shorter-
ife ICDs, our analysis of the diagnosis-related groups
uggest that institutions will have difficulty recovering the
osts of ICD pulse generator replacements unless the
eplacement device is an upgrade, e.g., from a single-
hamber to a dual-chamber model.
It is time to revise reimbursement methods to encourage
anufacturers to produce and hospitals to implant longer-
ife devices. Several approaches could be adopted by payers
nd offered by manufacturers, including a program that
ould cap device costs for the life of an individual patient
nd reward ICD longevity. Patients and payers would
enefit because the frequency of replacement surgery would
ecrease, and the cost-benefit of ICD therapy would im-
rove. Further, it is more reasonable for Medicare to focus
ts cost containment efforts on the actual costs associated
ith delivering ICD therapy than to limit reimbursable
ndications by arbitrary coverage decisions. Whatever the
olution, the problem is clear, i.e., the health economy is
acing a staggering expense. The SCD-HeFT study results
lone could double the number of ICD implants. The
edical community, payers, and industry must address this
ritical issue in 2005. If we begin now, most patients could
eceive a lifetime ICD pulse generator by 2007. Although
dditional strategies will be needed to control the costs of
CD therapy, longer-life models can narrow the mismatch
etween patient and device longevity.
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